A carregar...
CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model
Prexasertib (LY2606368) is a potent and selective small molecule inhibitor of cell-cycle checkpoint CHK1 and CHK2 protein kinases and is currently under clinical evaluation for treatment of pediatric malignancies. As a candidate therapy for pediatric Group 3 medulloblastoma (G3MB), prexasertib CNS p...
Na minha lista:
| Publicado no: | Eur J Pharm Sci |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6925336/ https://ncbi.nlm.nih.gov/pubmed/31669383 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejps.2019.105106 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|